MedTrace Logo

Raloxifene for Women With Alzheimer's Disease

NCT00368459 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2015-04-02

Study results available
· View outcomes & findings →

Summary

This is a multisite pilot randomized trial of raloxifene or placebo for the treatment of women with Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

raloxifene

Raloxifene is a selective estrogen receptor modulator

DRUG

Placebo

Identical appearing placebo

Sponsors & Collaborators

  • Kaiser Permanente

    collaborator OTHER

  • Indiana University

    collaborator OTHER

  • Southern Illinois University

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Dr Victor Henderson · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2011-03-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368459 on ClinicalTrials.gov